Wnt pathway components have promise as therapeutic targets, since more than 90% of colon cancers are triggered by mutations that overactivate this pathway, particularly in the tumor suppressor APC. However, as Wnt signaling is also required for normal intestinal homeostasis, the selective therapeutic targeting of oncogenic Wnt signaling remains a major challenge. This evidence concerns the gene APC and malignant colon neoplasm.